VHH Technologies
Isogenica specialises in VHHs – single-domain antibodies that offer exceptional robustness, flexibility, and scalability across varied therapeutic and diagnostic applications.
Discover the power of VHHs for faster antibody discovery and development
At diversities of 10^10 and 10^13, our VHH libraries are the most diverse synthetic VHH libraries on the market.
Learn about CIS Display™, a powerful antibody selection tool.
Tackling the challenge of short half-life for small-format antibody therapeutics.
FAQs
What makes your synthetic libraries unique?
Isogenica has built fully synthetic, humanized VHH libraries using structure-guided CDR diversification and human framework design. Combined with our cell-free CIS Display™ technology, they deliver ultra-high diversity (10¹⁰–10¹³) and rapid, high-fidelity screening without animal immunization.
How do synthetic and natural libraries differ?
Natural libraries depend on animal immune responses and are limited by species bias and sequence collapse. Synthetic libraries enable broader, controllable diversity and include human-framework designs optimised for developability and scalability.
Why does a fully synthetic, cell-free discovery approach matter for hard or high-risk targets?
It avoids immune bias and biological bottlenecks, allowing precise control over selection pressure for conserved, toxic, or conformationally complex targets.
How do you address developability risks early in discovery?
We prioritise human-aligned frameworks, apply sequence analytics, and use optional biophysical screening to identify candidates with favourable stability and manufacturability profiles.
Work with us
By partnering with our expert team, you’ll not only benefit from access to our state-of-the-art technology and expertise but also the perks of how we like to work with others. From start to finish we become an extended part of your team, keeping you updated and informed regularly on our progress. With our groundbreaking technology and expert guidance, Isogenica helps small to mid-sized biotech companies bring novel therapies to market faster— cutting typical discovery timelines in half by accelerating lead selection and reducing follow-on engineering requirements. Talk to us today and find out how we can accelerate your VHH discovery project.